To see the other types of publications on this topic, follow the link: Glucagon suppression.

Journal articles on the topic 'Glucagon suppression'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Glucagon suppression.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Arafat, A. M., F. H. Perschel, B. Otto, et al. "Glucagon Suppression of Ghrelin Secretion Is Exerted at Hypothalamus-Pituitary Level." Journal of Clinical Endocrinology & Metabolism 91, no. 9 (2006): 3528–33. http://dx.doi.org/10.1210/jc.2006-0225.

Full text
Abstract:
Abstract Context: The mechanisms underlying the well-known glucagon-induced satiety effect are unclear. Recently, we showed that glucagon induces a remarkable decrease in the orexigenic hormone ghrelin that might be responsible for this effect. Objective: The objective of this study was to evaluate the putative role of the hypothalamic pituitary axis in glucagon’s suppressive effect on ghrelin secretion. Design, Subjects, and Methods: Prospectively, we studied the endocrine and metabolic responses to im glucagon administration in 22 patients (16 males; age, 21–68 yr; body mass index, 28.1 ± 1.
APA, Harvard, Vancouver, ISO, and other styles
2

Weick, B. G., and S. Ritter. "Dose-related suppression of feeding by intraportal glucagon infusion in the rat." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 250, no. 4 (1986): R676—R681. http://dx.doi.org/10.1152/ajpregu.1986.250.4.r676.

Full text
Abstract:
Continuous intraportal infusion of pancreatic glucagon during a feeding test conducted in the dark phase of the circadian photoperiod produced a dose-related suppression of feeding in rats. At the end of the 30 min of infusion, food intake was suppressed 10% at the infusion rate of 0.33 micrograms X kg-1 X min-1 and 45% at the highest infusion rate studied (100 micrograms X kg-1 X min-1). At infusion rates of 33 and 100 micrograms X kg-1 X min-1, the suppression of cumulative intake persisted for 30 min after the termination of the infusion, but no effect on 24-h intake was observed. Glucagon'
APA, Harvard, Vancouver, ISO, and other styles
3

Urbano, Francesca, Antonino Di Pino, Roberto Scicali, et al. "Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy." European Journal of Endocrinology 181, no. 6 (2019): 579–90. http://dx.doi.org/10.1530/eje-19-0173.

Full text
Abstract:
Objective Statin therapy has been linked to an increased risk of type 2 diabetes in high-risk populations; however, the pathophysiology of this association remains to be clarified. We investigated glucagon suppression and its relationship with insulin resistance in prediabetic subjects undergoing atorvastatin therapy; in addition, we studied molecular insulin signaling in pancreatic α-cells exposed to atorvastatin in vitro. Design and methods Fifty subjects with prediabetes were divided into two groups based on atorvastatin therapy. All subjects underwent an oral glucose tolerance test. Early
APA, Harvard, Vancouver, ISO, and other styles
4

Lund, Asger, Tina Vilsbøll, Jonatan I. Bagger, Jens J. Holst, and Filip K. Knop. "The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes." American Journal of Physiology-Endocrinology and Metabolism 300, no. 6 (2011): E1038—E1046. http://dx.doi.org/10.1152/ajpendo.00665.2010.

Full text
Abstract:
Type 2 diabetes mellitus (T2DM) is associated with reduced suppression of glucagon during oral glucose tolerance test (OGTT), whereas isoglycemic intravenous glucose infusion (IIGI) results in normal glucagon suppression in these patients. We examined the role of the intestinal hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2) in this discrepancy. Glucagon responses were measured during a 3-h 50-g OGTT ( day A) and an IIGI ( day B) in 10 patients with T2DM [age (mean ± SE), 51 ± 3 yr; body mass index, 33 ± 2 kg/m2;
APA, Harvard, Vancouver, ISO, and other styles
5

Bansal, Pritpal, and Qinghua Wang. "Insulin as a physiological modulator of glucagon secretion." American Journal of Physiology-Endocrinology and Metabolism 295, no. 4 (2008): E751—E761. http://dx.doi.org/10.1152/ajpendo.90295.2008.

Full text
Abstract:
Glucose homeostasis is regulated primarily by the opposing actions of insulin and glucagon, hormones that are secreted by pancreatic islets from β-cells and α-cells, respectively. Insulin secretion is increased in response to elevated blood glucose to maintain normoglycemia by stimulating glucose transport in muscle and adipocytes and reducing glucose production by inhibiting gluconeogenesis in the liver. Whereas glucagon secretion is suppressed by hyperglycemia, it is stimulated during hypoglycemia, promoting hepatic glucose production and ultimately raising blood glucose levels. Diabetic hyp
APA, Harvard, Vancouver, ISO, and other styles
6

Le Marchand, Sylvain J., and David W. Piston. "Glucose Suppression of Glucagon Secretion." Journal of Biological Chemistry 285, no. 19 (2010): 14389–98. http://dx.doi.org/10.1074/jbc.m109.069195.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shah, Pankaj, Ananda Basu, Rita Basu, and Robert Rizza. "Impact of lack of suppression of glucagon on glucose tolerance in humans." American Journal of Physiology-Endocrinology and Metabolism 277, no. 2 (1999): E283—E290. http://dx.doi.org/10.1152/ajpendo.1999.277.2.e283.

Full text
Abstract:
People with type 2 diabetes have defects in both α- and β-cell function. To determine whether lack of suppression of glucagon causes hyperglycemia when insulin secretion is impaired but not when insulin secretion is intact, twenty nondiabetic subjects were studied on two occasions. On both occasions, a “prandial” glucose infusion was given over 5 h while endogenous hormone secretion was inhibited. Insulin was infused so as to mimic either a nondiabetic ( n = 10) or diabetic ( n = 10) postprandial profile. Glucagon was infused at a rate of 1.25 ng ⋅ kg−1 ⋅ min−1, beginning either at time zero t
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, Xi, Enrique Maldonado, Ralph A. DeFronzo, and Devjit Tripathy. "Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function." Journal of Clinical Endocrinology & Metabolism 106, no. 5 (2021): 1398–409. http://dx.doi.org/10.1210/clinem/dgab019.

Full text
Abstract:
Abstract Aim To examine the relationship between plasma glucagon levels and insulin sensitivity and insulin secretion in obese subjects. Methods Suppression of plasma glucagon was examined in 275 obese Hispanic Americans with varying glucose tolerance. All subjects received a 2-hour oral glucose tolerance test (OGTT) and a subset (n = 90) had euglycemic hyperinsulinemic clamp. During OGTT, we quantitated suppression of plasma glucagon concentration, Matsuda index of insulin sensitivity, and insulin secretion/insulin resistance (disposition) index. Plasma glucagon suppression was compared betwe
APA, Harvard, Vancouver, ISO, and other styles
9

Lewis, Gary F., Mladen Vranic, and Adria Giacca. "Role of free fatty acids and glucagon in the peripheral effect of insulin on glucose production in humans." American Journal of Physiology-Endocrinology and Metabolism 275, no. 1 (1998): E177—E186. http://dx.doi.org/10.1152/ajpendo.1998.275.1.e177.

Full text
Abstract:
We have shown previously that the greater suppression of endogenous glucose production (GP) with equimolar peripheral vs. portal insulin cannot be detected or is minimally reversed when the insulin-induced suppression of either free fatty acids (FFA) or glucagon alone is prevented. The present experiments were designed to minimize the insulin suppression of both glucagon and FFA in an attempt to further examine the mechanism of insulin’s peripheral effect on GP. In nine healthy men, we investigated the effect of limiting the insulin suppression of both FFA and glucagon by infusing heparin (250
APA, Harvard, Vancouver, ISO, and other styles
10

Schrader, Henning, Bjoern A. Menge, Thomas G. K. Breuer, et al. "Impaired Glucose-Induced Glucagon Suppression after Partial Pancreatectomy." Journal of Clinical Endocrinology & Metabolism 94, no. 8 (2009): 2857–63. http://dx.doi.org/10.1210/jc.2009-0826.

Full text
Abstract:
Introduction: The glucose-induced decline in glucagon levels is often lost in patients with type 2 diabetes. It is unclear whether this is due to an independent defect in α-cell function or secondary to the impairment in insulin secretion. We examined whether a partial pancreatectomy in humans would also impair postchallenge glucagon concentrations and, if so, whether this could be attributed to the reduction in insulin levels. Patients and Methods: Thirty-six patients with pancreatic tumours or chronic pancreatitis were studied before and after approximately 50% pancreatectomy with a 240-min
APA, Harvard, Vancouver, ISO, and other styles
11

Adams, Jon D., Aoife M. Egan, Marcello C. Laurenti, et al. "Insulin secretion and action and the response of endogenous glucose production to a lack of glucagon suppression in nondiabetic subjects." American Journal of Physiology-Endocrinology and Metabolism 321, no. 5 (2021): E728—E736. http://dx.doi.org/10.1152/ajpendo.00284.2021.

Full text
Abstract:
In prediabetes, anthropometric characteristics as well as insulin action do not alter the hepatic response to glucagon. The postprandial suppression or lack of suppression of glucagon secretion is an important factor governing postprandial glucose tolerance independent of insulin secretion.
APA, Harvard, Vancouver, ISO, and other styles
12

Wewer Albrechtsen, Nicolai J., Simon Veedfald, Astrid Plamboeck, et al. "Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion." Journal of Diabetes Research 2016 (2016): 1–5. http://dx.doi.org/10.1155/2016/8352957.

Full text
Abstract:
Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, important. We studied the ability of immunoassays based on four different technologies to detect changes in levels of glucagon under conditions where glucagon levels are strongly suppressed. To our surprise, the most advanced technological methods, employing electrochemiluminescence or homogeneous time res
APA, Harvard, Vancouver, ISO, and other styles
13

Meier, Juris J., Sandra Ueberberg, Simone Korbas та Stephan Schneider. "Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass". American Journal of Physiology-Endocrinology and Metabolism 300, № 4 (2011): E717—E723. http://dx.doi.org/10.1152/ajpendo.00315.2010.

Full text
Abstract:
Impaired suppression of glucagon levels after oral glucose or meal ingestion is a hallmark of type 2 diabetes. Whether hyperglucagonemia after a β-cell loss results from a functional upregulation of glucagon secretion or an increase in α-cell mass is yet unclear. CD-1 mice were treated with streptozotocin (STZ) or saline. Pancreatic tissue was collected after 14, 21, and 28 days and examined for α- and β-cell mass and turnover. Intraperitoneal (ip) glucose tolerance tests were performed at day 28 as well as after 12 days of subcutaneous insulin treatment, and glucose, insulin, and glucagon lev
APA, Harvard, Vancouver, ISO, and other styles
14

Bellinger, L. L., and F. E. Williams. "Glucagon and epinephrine suppression of food intake in liver-denervated rats." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 251, no. 2 (1986): R349—R358. http://dx.doi.org/10.1152/ajpregu.1986.251.2.r349.

Full text
Abstract:
Milk intake suppression after intraperitoneal glucagon and epinephrine injections was studied in liver-denervated [hepatic vagal branch transection (VAG-B), hepatic artery-portal vein denervations (H-ART), or total denervation (TOTAL)] and sham-operated rats (SHAM). In experiment 1, glucagon (500 micrograms/kg, Sigma) had no effect on 30 min of milk intake but produced hyperglycemia in all groups. Glucagon (750 micrograms/kg, Sigma; 400 micrograms/kg, Lilly) decreased intake in all groups, as did epinephrine (30 micrograms/kg). In experiment 2, TOTAL and SHAM were tested with 50, 100, and 400
APA, Harvard, Vancouver, ISO, and other styles
15

Basu, Ananda, Pankaj Shah, Michael Nielsen, Rita Basu, and Robert A. Rizza. "Effects of Type 2 Diabetes on the Regulation of Hepatic Glucose Metabolism." Journal of Investigative Medicine 52, no. 6 (2004): 366–74. http://dx.doi.org/10.1136/jim-52-06-30.

Full text
Abstract:
Glucose production is inappropriately increased in people with type 2 diabetes both before and after food ingestion. Excessive postprandial glucose production occurs in the presence of decreased and delayed insulin secretion and lack of suppression of glucagon release. These abnormalities in hormone secretion, coupled with impaired insulin-induced suppression of glucose production and stimulation of splanchnic glucose uptake, likely account in large part for the excessive amounts of glucose that reach the systemic circulation for disposal by peripheral tissues following food ingestion. In cont
APA, Harvard, Vancouver, ISO, and other styles
16

Basu, Ananda, Pankaj Shah, Michael Nielsen, Rita Basu, and Robert A. Rizza. "Effects of Type 2 Diabetes on the Regulation of Hepatic Glucose Metabolism." Journal of Investigative Medicine 52, no. 6 (2004): 366–74. http://dx.doi.org/10.1177/108155890405200630.

Full text
Abstract:
Glucose production is inappropriately increased in people with type 2 diabetes both before and after food ingestion. Excessive postprandial glucose production occurs in the presence of decreased and delayed insulin secretion and lack of suppression of glucagon release. These abnormalities in hormone secretion, coupled with impaired insulin-induced suppression of glucose production and stimulation of splanchnic glucose uptake, likely account in large part for the excessive amounts of glucose that reach the systemic circulation for disposal by peripheral tissues following food ingestion. In cont
APA, Harvard, Vancouver, ISO, and other styles
17

Bradley, D. C., and R. N. Bergman. "Restoration of stable metabolic conditions during islet suppression in dogs." American Journal of Physiology-Endocrinology and Metabolism 262, no. 4 (1992): E532—E538. http://dx.doi.org/10.1152/ajpendo.1992.262.4.e532.

Full text
Abstract:
These studies were undertaken to examine the stability of metabolic conditions during islet suppression with fixed-rate insulin and glucagon replacement. Somatostatin was infused peripherally at 0.8 microgram.min-1.kg-1, insulin was infused intraportally at 200 microU.min-1.kg-1, and glucagon was infused intraportally at 0, 0.6, 1, 2, 5, or 20 ng.min-1.kg-1 in conscious overnight-fasted dogs. [3-3H]glucose was infused for measurement of glucose kinetics. During infusion, plasma insulin was 7.2 +/- 0.4 microU/ml. Plasma glucagon rose linearly with glucagon dose, achieving basal levels at 2 ng.m
APA, Harvard, Vancouver, ISO, and other styles
18

Raju, Bharathi, and Philip E. Cryer. "Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon?" American Journal of Physiology-Endocrinology and Metabolism 289, no. 2 (2005): E181—E186. http://dx.doi.org/10.1152/ajpendo.00460.2004.

Full text
Abstract:
The prevalent view is that the postabsorptive plasma glucose concentration is maintained within the physiological range by the interplay of the glucose-lowering action of insulin and the glucose-raising action of glucagon. It is supported by a body of evidence derived from studies of suppression of glucagon (and insulin, among other effects) with somatostatin in animals and humans, immunoneutralization of glucagon, defective glucagon synthesis, diverse mutations, and absent or reduced glucagon receptors in animals and glucagon antagonists in cells, animals, and humans. Many of these studies ar
APA, Harvard, Vancouver, ISO, and other styles
19

Kelly, Andrea, Saba Sheikh, Darko Stefanovski, et al. "Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance." Journal of Clinical Endocrinology & Metabolism 106, no. 9 (2021): 2617–34. http://dx.doi.org/10.1210/clinem/dgab365.

Full text
Abstract:
Abstract Purpose Impaired incretin secretion may contribute to the defective insulin secretion and abnormal glucose tolerance (AGT) that associate with worse clinical outcomes in pancreatic insufficient cystic fibrosis (PI-CF). The study objective was to test the hypothesis that dipeptidyl peptidase-4 (DPP-4) inhibitor-induced increases in intact incretin hormone [glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)] concentrations augment insulin secretion and glucagon suppression and lower postprandial glycemia in PI-CF with AGT. Methods 26 adults from Child
APA, Harvard, Vancouver, ISO, and other styles
20

Geary, Nori. "Postprandial Suppression of Glucagon Secretion: A Puzzlement." Diabetes 66, no. 5 (2017): 1123–25. http://dx.doi.org/10.2337/dbi16-0075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Yu, Qian, Bao Khanh Lai, Parvin Ahooghalandari та ін. "γ-Hydroxybutyrate does not mediate glucose inhibition of glucagon secretion". Journal of Biological Chemistry 295, № 16 (2020): 5419–26. http://dx.doi.org/10.1074/jbc.ra119.009577.

Full text
Abstract:
Hypersecretion of glucagon from pancreatic α-cells strongly contributes to diabetic hyperglycemia. Moreover, failure of α-cells to increase glucagon secretion in response to falling blood glucose concentrations compromises the defense against hypoglycemia, a common complication in diabetes therapy. However, the mechanisms underlying glucose regulation of glucagon secretion are poorly understood and likely involve both α-cell–intrinsic and intraislet paracrine signaling. Among paracrine factors, glucose-stimulated release of the GABA metabolite γ-hydroxybutyric acid (GHB) from pancreatic β-cell
APA, Harvard, Vancouver, ISO, and other styles
22

Hermansen, K. "Effects of galanin on the release of insulin, glucagon and somatostatin from the isolated, perfused dog pancreas." Acta Endocrinologica 119, no. 1 (1988): 91–98. http://dx.doi.org/10.1530/acta.0.1190091.

Full text
Abstract:
Abstract. Galanin is a 29 amino acid peptide which has been found in intrapancreatic nerves. The effects of galanin, adrenergic and cholinergic blockade as well as somatostatin on the hormone release from the isolated perfused dog pancreas were studied. It was found that galanin dose-dependently inhibited insulin (P < 0.001) and somatostatin (P < 0.001) but not glucagon secretion at normal glucose levels. The lowest galanin concentration that caused a significant suppression of insulin and somatostatin secretion was 10−11and 10−10 mol/l, respectively. Similar effects were evident during
APA, Harvard, Vancouver, ISO, and other styles
23

Al-Massadi, Omar, Johan Fernø, Carlos Diéguez, Ruben Nogueiras, and Mar Quiñones. "Glucagon Control on Food Intake and Energy Balance." International Journal of Molecular Sciences 20, no. 16 (2019): 3905. http://dx.doi.org/10.3390/ijms20163905.

Full text
Abstract:
Glucagon exerts pleiotropic actions on energy balance and has emerged as an attractive target for the treatment of diabetes and obesity in the last few years. Glucagon reduces body weight and adiposity by suppression of appetite and by modulation of lipid metabolism. Moreover, this hormone promotes weight loss by activation of energy expenditure and thermogenesis. In this review, we cover these metabolic actions elicited by glucagon beyond its canonical regulation of glucose metabolism. In addition, we discuss recent developments of therapeutic approaches in the treatment of obesity and diabet
APA, Harvard, Vancouver, ISO, and other styles
24

Wewer Albrechtsen, Nicolai J., Rune E. Kuhre, Johanne A. Windeløv, et al. "Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes." American Journal of Physiology-Endocrinology and Metabolism 311, no. 2 (2016): E302—E309. http://dx.doi.org/10.1152/ajpendo.00119.2016.

Full text
Abstract:
Glucagon is a metabolically important hormone, but many aspects of its physiology remain obscure, because glucagon secretion is difficult to measure in mice and rats due to methodological inadequacies. Here, we introduce and validate a low-volume, enzyme-linked immunosorbent glucagon assay according to current analytical guidelines, including tests of sensitivity, specificity, and accuracy, and compare it, using the Bland-Altman algorithm and size-exclusion chromatography, with three other widely cited assays. After demonstrating adequate performance of the assay, we measured glucagon secretio
APA, Harvard, Vancouver, ISO, and other styles
25

Braatvedt, G. D., A. Stanners, P. G. Newrick, M. Halliwell, and R. J. M. Corrall. "Evidence against a putative role for glucagon as a physiological splanchnic vasodilator in man." Clinical Science 84, no. 2 (1993): 193–99. http://dx.doi.org/10.1042/cs0840193.

Full text
Abstract:
1. Previous studies have suggested that glucagon in supraphysiological doses may mediate postprandial and hypoglycaemia-induced splanchnic vasodilatation in man and experimental animals. There are no reported studies investigating the role of glucagon in doses producing circulating concentrations within the physiological range. 2. Two separate studies were performed. In study 1, superior mesenteric artery blood flow was measured by Doppler ultrasound in six normal subjects during either saline or glucagon infusion at 1, 3 and 6 ng min−1 kg−1, which resulted in circulating glucagon levels withi
APA, Harvard, Vancouver, ISO, and other styles
26

Knop, Filip K. "EJE PRIZE 2018: A gut feeling about glucagon." European Journal of Endocrinology 178, no. 6 (2018): R267—R280. http://dx.doi.org/10.1530/eje-18-0197.

Full text
Abstract:
Hyperglucagonaemia (in the fasting as well as in the postprandial state) is considered a core pathophysiological component of diabetes and is found to contribute substantially to the hyperglycaemic state of diabetes. Hyperglucagonaemia is usually viewed upon as a consequence of pancreatic alpha cell insensitivity to the glucagon-suppressive effects of glucose and insulin. Since we observed that the well-known hyperglucagonaemic response to oral glucose in patients with type 2 diabetes is exchanged by normal suppression of plasma glucagon levels following isoglycaemic intravenous glucose admini
APA, Harvard, Vancouver, ISO, and other styles
27

Lavelle-Jones, M., M. H. Scott, O. Kolterman, A. H. Rubenstein, J. M. Olefsky, and A. R. Moossa. "Selective suppression of hepatic glucose output by human proinsulin in the dog." American Journal of Physiology-Endocrinology and Metabolism 252, no. 2 (1987): E230—E236. http://dx.doi.org/10.1152/ajpendo.1987.252.2.e230.

Full text
Abstract:
By using the euglycemic glucose-clamp technique we have observed the effects of comparable low dose proinsulin and insulin infusions on isotopically determined glucose turnover in 20 anesthetized dogs. In each animal somatostatin (SRIF) infusion was used to suppress endogenous pancreatic hormone secretion and basal glucagon was replaced. Peripheral proinsulin (0.083 micrograms X kg-1 X min-1) and insulin (350 microU X kg-1 X min-1) levels 15- to 20-fold higher than insulin on a molar basis, based on previous observations that proinsulin has only 5-10% the biologic potency of insulin. Three gro
APA, Harvard, Vancouver, ISO, and other styles
28

Brubaker, Patricia L., Tsutomu Kazumi, Tsutomu Hirano, Mladen Vranic, and George Steiner. "Failure of chronic hyperinsulinemia to suppress pancreatic glucagon in vivo in the rat." Canadian Journal of Physiology and Pharmacology 69, no. 3 (1991): 437–43. http://dx.doi.org/10.1139/y91-066.

Full text
Abstract:
To determine the effects of chronic hyperinsulinemia on glucagon release, rats were made hyperinsulinemic for 14 days by supplementation of drinking water with sucrose (10%; sucrose-fed) to increase endogenous release or by implantation of osmotic minipumps (subcutaneous, s.c; or intraperitoneal, i.p.) to deliver exogenous insulin (6 U/day). Both s.c. and i.p. rats also had sucrose in the drinking water to prevent hypoglycemia. Plasma insulin levels were significantly elevated in sucrose-fed, s.c, and i.p. rats. However, glucose levels were significantly elevated in sucrose-fed rats only. Surp
APA, Harvard, Vancouver, ISO, and other styles
29

Welles, Jaclyn E., Michael D. Dennis, Leonard S. Jefferson, and Scot R. Kimball. "Glucagon-dependent suppression of mTORC1 is associated with upregulation of hepatic FGF21 mRNA translation." American Journal of Physiology-Endocrinology and Metabolism 319, no. 1 (2020): E26—E33. http://dx.doi.org/10.1152/ajpendo.00555.2019.

Full text
Abstract:
Fibroblast growth factor 21 (FGF21) is a peptide hormone that acts to enhance insulin sensitivity and reverse many of the metabolic defects associated with consumption of a high-fat diet. Recent studies show that the liver is the primary source of FGF21 in the blood and that hepatic FGF21 expression is upregulated by glucagon. Interestingly, glucagon acts to upregulate FGF21 production by primary cultures of rat hepatocytes and H4IIE and HepG2 hepatocarcinoma cells independent of changes in FGF21 mRNA abundance, suggesting that FGF21 protein expression is regulated posttranscriptionally. Based
APA, Harvard, Vancouver, ISO, and other styles
30

St. Onge, Erin L., Shannon A. Miller, and James R. Taylor. "Novel Approaches to the Treatment of Type 2 Diabetes." Journal of Pharmacy Practice 22, no. 3 (2009): 320–32. http://dx.doi.org/10.1177/0897190008326578.

Full text
Abstract:
The emergence of the glucoregulatory hormone, glucagon-like peptide-1, has expanded our understanding of glucose homeostasis. The glucoregulatory actions of glucagon-like peptide-1 include enhancement of glucose-dependent insulin secretion, suppression of inappropriately elevated glucagon secretion, slowing of gastric emptying, and reduction of food intake. Two approaches have been developed to potentiate the effects of glucagon-like peptide-1 in those with type 2 diabetes. The glucagon-like peptide-1 analogs, such as exenatide, and dipeptidyl peptidase-IV inhibitors, such as sitagliptin, are
APA, Harvard, Vancouver, ISO, and other styles
31

Breckenridge, Suzanne M., Bharathi Raju, Ana Maria Arbelaez, Bruce W. Patterson, Benjamin A. Cooperberg, and Philip E. Cryer. "Basal insulin, glucagon, and growth hormone replacement." American Journal of Physiology-Endocrinology and Metabolism 293, no. 5 (2007): E1303—E1310. http://dx.doi.org/10.1152/ajpendo.00325.2007.

Full text
Abstract:
Conclusions drawn from the pancreatic (or islet) clamp technique (suppression of endogenous insulin, glucagon, and growth hormone secretion with somatostatin and replacement of basal hormone levels by intravenous infusion) are critically dependent on the biological appropriateness of the selected doses of the replaced hormones. To assess the appropriateness of representative doses we infused saline alone, insulin (initially 0.20 mU·kg−1·min−1) alone, glucagon (1.0 ng·kg−1·min−1) alone, and growth hormone (3.0 ng·kg−1·min−1) alone intravenously for 4 h in 13 healthy individuals. That dose of in
APA, Harvard, Vancouver, ISO, and other styles
32

Giugliano, D., D. Cozzolino, A. Ceriello, T. Salvatore, G. Paolisso, and R. Torella. "Beta-endorphin and islet hormone release in humans: evidence for interference with cAMP." American Journal of Physiology-Endocrinology and Metabolism 257, no. 3 (1989): E361—E366. http://dx.doi.org/10.1152/ajpendo.1989.257.3.e361.

Full text
Abstract:
The present studies were undertaken to characterize further the influence of synthetic human beta-endorphin (0.5 mg/h) on insulin and glucagon responses to intravenous glucose in humans. Infusion of beta-endorphin in 10 normal volunteers caused a clear-cut inhibition of the overall insulin responses to a glucose pulse (0.33 g/kg iv) with values of glucose disappearance rates in the diabetic range [0.89 +/- 0.09 (P less than 0.01) vs. saline 1.82 +/- 0.15%/min]. Glucose-induced glucagon suppression was significantly lower during beta-endorphin, a fact that could have contributed to the reduced
APA, Harvard, Vancouver, ISO, and other styles
33

Lewis, G. F., M. Vranic, and A. Giacca. "Glucagon enhances the direct suppressive effect of insulin on hepatic glucose production in humans." American Journal of Physiology-Endocrinology and Metabolism 272, no. 3 (1997): E371—E378. http://dx.doi.org/10.1152/ajpendo.1997.272.3.e371.

Full text
Abstract:
The present study examines the role of glucagon in modulating the hepatic and extrahepatic effects of insulin on hepatic glucose production (HGP). We infused glucagon at a constant rate (0.65 ng x kg(-1) x min(-1)) during equimolar portal and peripheral insulin delivery in seven healthy males by our previously published tolbutamide infusion method. In contrast to our previous study, in which glucagon fell by approximately 30% during hyperinsulinemia and suppression of HGP was significantly greater with equimolar peripheral than with portal insulin delivery, HGP was actually suppressed to a les
APA, Harvard, Vancouver, ISO, and other styles
34

Shestakova, E. A., A. V. Ilyin, A. D. Deev, M. V. Shestakova, and I. I. Dedov. "Regulation of glucagon secretion by incretin-like hormone family in the patients at risk of developing type 2 diabetes mellitus." Problems of Endocrinology 60, no. 1 (2014): 32–35. http://dx.doi.org/10.14341/probl201460132-35.

Full text
Abstract:
The study included 127 patients with type 2 diabetes (T2D) risk factors, who underwent oral glucose tolerance test (75 g glucose) with pancreatic and incretin hormones estimated in fasting state, at 30 and 120 minutes after glucose load. According to the test results the population was divided into 3 groups: group with normal glucose tolerance (NGT), group with high risk of diabetes developing (impaired glucose tolerance (IGT) and impaired fasting glycemia (IFG)) and newly-diagnosed T2D. The stimulated glucagon secretion was suppressed in NGT group, whereas in T2D patients there was an increas
APA, Harvard, Vancouver, ISO, and other styles
35

Elliott, Amicia D., Alessandro Ustione та David W. Piston. "Somatostatin and insulin mediate glucose-inhibited glucagon secretion in the pancreatic α-cell by lowering cAMP". American Journal of Physiology-Endocrinology and Metabolism 308, № 2 (2015): E130—E143. http://dx.doi.org/10.1152/ajpendo.00344.2014.

Full text
Abstract:
The dysregulation of glucose-inhibited glucagon secretion from the pancreatic islet α-cell is a critical component of diabetes pathology and metabolic disease. We show a previously uncharacterized [Ca2+]i-independent mechanism of glucagon suppression in human and murine pancreatic islets whereby cAMP and PKA signaling are decreased. This decrease is driven by the combination of somatostatin, which inhibits adenylyl cyclase production of cAMP via the Gαi subunit of the SSTR2, and insulin, which acts via its receptor to activate phosphodiesterase 3B and degrade cytosolic cAMP. Our data indicate
APA, Harvard, Vancouver, ISO, and other styles
36

Yang, Wanbao, Hui Yan, Quan Pan, et al. "Glucagon regulates hepatic mitochondrial function and biogenesis through FOXO1." Journal of Endocrinology 241, no. 3 (2019): 265–78. http://dx.doi.org/10.1530/joe-19-0081.

Full text
Abstract:
Glucagon promotes hepatic glucose production maintaining glucose homeostasis in the fasting state. Glucagon maintains at high level in both diabetic animals and human, contributing to hyperglycemia. Mitochondria, a major place for glucose oxidation, are dysfunctional in diabetic condition. However, whether hepatic mitochondrial function can be affected by glucagon remains unknown. Recently, we reported that FOXO1 is an important mediator in glucagon signaling in control of glucose homeostasis. In this study, we further assessed the role of FOXO1 in the action of glucagon in the regulation of h
APA, Harvard, Vancouver, ISO, and other styles
37

Strowski, Mathias Z., Doreen E. Cashen, Elizabeth T. Birzin, et al. "Antidiabetic Activity of a Highly Potent and Selective Nonpeptide Somatostatin Receptor Subtype-2 Agonist." Endocrinology 147, no. 10 (2006): 4664–73. http://dx.doi.org/10.1210/en.2006-0274.

Full text
Abstract:
Somatostatin inhibits both glucagon and insulin secretion. Glucagon significantly contributes to hyperglycemia in type 2 diabetes. Despite its function in the inhibition of glucagon secretion, somatostatin fails to reduce hyperglycemia in type 2 diabetes, due to a parallel suppression of insulin secretion. Five pharmacologically distinct somatostatin receptor subtypes (sst1–sst5) mediate the effects of somatostatin on a cellular level. Pancreatic A cells express sst2, whereas B cells express sst5. In this study, we describe a novel approach to the treatment of type 2 diabetes using a highly ss
APA, Harvard, Vancouver, ISO, and other styles
38

Lund, Asger, Jonatan I. Bagger, Mikkel Christensen, et al. "Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion." Journal of Clinical Endocrinology & Metabolism 101, no. 11 (2016): 4377–84. http://dx.doi.org/10.1210/jc.2016-1948.

Full text
Abstract:
Context: Oral glucose ingestion elicits a larger insulin response and delayed suppression of glucagon compared to isoglycemic IV glucose infusion (IIGI). Objective: We studied whether these differences translate into effects on endogenous glucose production (EGP) and glucose disposal in patients with type 2 diabetes and nondiabetic control subjects. Design: This was a single-blinded, randomized, crossover study. Setting: The study was conducted at a specialized research unit. Participants: Ten patients with type 2 diabetes (age, [mean ± SD] 57.1 ± 6.7 years; body mass index, 29.0 ± 4.3 kg/m2;
APA, Harvard, Vancouver, ISO, and other styles
39

Klaff, L. J., and G. J. Taborsky. "Role of pancreatic somatostatin in determining glucagon response to arginine and morphine." American Journal of Physiology-Endocrinology and Metabolism 252, no. 6 (1987): E751—E755. http://dx.doi.org/10.1152/ajpendo.1987.252.6.e751.

Full text
Abstract:
It has been proposed that pancreatic somatostatin (SS) tonically inhibits pancreatic glucagon secretion. In keeping with this hypothesis, we have previously shown that infusion of a nonimmunoreactive analogue of SS, [D-Ala5,D-Trp8]somatostatin (SSa), which in low doses inhibits SS secretion without inhibiting glucagon or insulin secretion, is associated with a large increase in glucagon and small increase in insulin secretion. Although direct stimulation of the alpha- and beta-cells by the analogue could not be excluded, high doses of the analogue appeared to inhibit insulin and glucagon secre
APA, Harvard, Vancouver, ISO, and other styles
40

Yoo, Soyeon, Dongkyu Kim, and Gwanpyo Koh. "The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes." Journal of Clinical Medicine 10, no. 11 (2021): 2487. http://dx.doi.org/10.3390/jcm10112487.

Full text
Abstract:
Background: We aimed to investigate the changes in glucagon levels in people with diabetes after the ingestion of a mixed meal and the correlations of variation in glucagon levels with incretin and clinico-biochemical characteristics. Methods: Glucose, C-peptide, glucagon, intact glucagon-like peptide 1 (iGLP-1), and intact glucose-dependent insulinotropic polypeptide (iGIP) were measured in blood samples collected from 317 people with diabetes before and 30 min after the ingestion of a standard mixed meal. The delta (Δ) is the 30-min value minus the basal value. Results: At 30 min after meal
APA, Harvard, Vancouver, ISO, and other styles
41

Morais, Tiago, Alexandre L. Seabra, Bárbara G. Patrício, et al. "Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity." Metabolites 13, no. 5 (2023): 587. http://dx.doi.org/10.3390/metabo13050587.

Full text
Abstract:
Visceral adipose tissue (VAT) metabolic fingerprints differ according to body mass index (BMI) and glycemic status. Glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon are gut-associated hormones that play an important role in regulating energy and glucose homeostasis, although their metabolic actions in VAT are still poorly characterized. Our aim was to assess whether GLP-1, GIP and glucagon influence the VAT metabolite profile. To achieve this goal, VAT harvested during elective surgical procedures from individuals (N = 19) with different BMIs and
APA, Harvard, Vancouver, ISO, and other styles
42

Filippello, Agnese, Alessandra Scamporrino, Stefania Di Mauro, et al. "Direct Effects of D-Chiro-Inositol on Insulin Signaling and Glucagon Secretion of Pancreatic Alpha Cells." Biomolecules 10, no. 10 (2020): 1404. http://dx.doi.org/10.3390/biom10101404.

Full text
Abstract:
The insulin resistance state of pancreatic α-cells seems to be related to glucagon hypersecretion in type 2 diabetes. Treatment that can improve the insulin sensitivity of α-cells could control glucagon levels in patients with diabetes mellitus. The aim of this study was to investigate the preventive role of D-chiro-inositol (DCI), which has insulin receptor-sensitizer effects on insulin signaling pathways and glucagon secretion in pancreatic α-TC1 clone 6 cells. Cells were chronically treated with palmitate to induce insulin resistance in the presence/absence of DCI. DCI treatment improved th
APA, Harvard, Vancouver, ISO, and other styles
43

Lam, Karen S. L., Rose T. T. Yeung, Patricia W. M. Ho, and S. K. Lam. "Glucose intolerance in thyrotoxicosis roles of insulin, glucagon and somatostatin." Acta Endocrinologica 114, no. 2 (1987): 228–34. http://dx.doi.org/10.1530/acta.0.1140228.

Full text
Abstract:
Abstract. The responses in plasma glucose, insulin, C-peptide, glucagon and somatostatin to an oral glucose load were studied in 10 thyrotoxic patients and 10 matched euthyroid controls. The thyrotoxic patients had higher mean fasting plasma glucose (P < 0.05) and responded to oral glucose with an earlier peak at 30 min which was higher than the corresponding glucose level in the controls (P < 0.05). Impaired glucose tolerance was found in 3 patients. Fasting insulin and C-peptide levels were normal in the thyrotoxic patients when corrected for the higher glucose levels. Following glucos
APA, Harvard, Vancouver, ISO, and other styles
44

Gross, R., та P. Mialhe. "Glucose, β adrenergic effects, and pancreatic endocrine function in the isolated perfused duck pancreas". Acta Endocrinologica 115, № 1 (1987): 105–11. http://dx.doi.org/10.1530/acta.0.1150105.

Full text
Abstract:
Abstract. Duck isolated perfused pancreas was used to assess glucose, adrenergic mediated effects and pancreatic function interrelationships. A moderate physiological 50% increase in glucose level, corresponding closely to the difference observed between 24-h-fasted and fed animals, induced a significant decrease of pancreatic glucagon not due to a rise in somatostatin secretion. The great responsiveness of the A cell was still found after glucagon stimulation by catecholamines or β adrenergic agonism. Insulin was irresponsive to the glucose load we used, suggesting that glucose-induced glucag
APA, Harvard, Vancouver, ISO, and other styles
45

Silvestre, R. A., J. Rodrı́guez-Gallardo, C. Jodka, et al. "Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas." American Journal of Physiology-Endocrinology and Metabolism 280, no. 3 (2001): E443—E449. http://dx.doi.org/10.1152/ajpendo.2001.280.3.e443.

Full text
Abstract:
Amylin, a peptide hormone from pancreatic β-cells, is reported to inhibit insulin secretion in vitro and in vivo and to inhibit nutrient-stimulated glucagon secretion in vivo. However, it has been reported not to affect arginine-stimulated glucagon secretion in vitro. To resolve if the latter resulted from inactive peptide (a problem in the early literature), those experiments were repeated here with well-characterized peptide and found to be valid. In isolated perfused rat pancreas preparations, coperfusion with 1 nM amylin had no effect on arginine-, carbachol-, or vasoactive intestinal pept
APA, Harvard, Vancouver, ISO, and other styles
46

Prigeon, Ronald L., Shaista Quddusi, Breay Paty, and David A. D'Alessio. "Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect." American Journal of Physiology-Endocrinology and Metabolism 285, no. 4 (2003): E701—E707. http://dx.doi.org/10.1152/ajpendo.00024.2003.

Full text
Abstract:
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that stimulates insulin secretion and decreases glucagon release. It has been hypothesized that GLP-1 also reduces glycemia independent of its effect on islet hormones. Based on preliminary evidence that GLP-1 has independent actions on endogenous glucose production, we undertook a series of experiments that were optimized to address this question. The effect of GLP-1 on glucose appearance (Ra) and glucose disposal (Rd) was measured in eight men during a pancreatic clamp that was performed by infusing octreotide to suppress secretion of
APA, Harvard, Vancouver, ISO, and other styles
47

Dinneen, S., A. Alzaid, D. Turk, and R. Rizza. "Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM." Diabetologia 38, no. 3 (1995): 337–43. http://dx.doi.org/10.1007/s001250050290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Dinneen, S., A. Alzaid, D. Turk, and R. Rizza. "Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM." Diabetologia 38, no. 3 (1995): 337–43. http://dx.doi.org/10.1007/bf00400639.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Hare, Kristine J., Tina Vilsbøll, Jens J. Holst, and Filip K. Knop. "Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes." American Journal of Physiology-Endocrinology and Metabolism 298, no. 4 (2010): E832—E837. http://dx.doi.org/10.1152/ajpendo.00700.2009.

Full text
Abstract:
Hyperglucagonemia following oral glucose ingestion in patients with type 1 diabetes (and type 2 diabetes) has been claimed to result from impaired intraislet insulin inhibition of glucagon. We looked at plasma glucagon responses to the oral glucose tolerance test (OGTT) and isoglycemic intravenous glucose infusion (IIGI) in patients with type 1 diabetes. Nine patients without residual β-cell function [age: 25 ± 9 yr; body mass index (BMI): 24 ± 2 kg/m2; fasting plasma glucose (FPG): 9.5 ± 2.1 mM; Hb A1c: 8.4 ± 1.2% (mean ± SD)] and eight healthy subjects (age: 28 ± 5 yr; BMI: 24 ± 3 kg/m2; FPG
APA, Harvard, Vancouver, ISO, and other styles
50

Arafat, M. A., B. Otto, H. Rochlitz, et al. "Glucagon inhibits ghrelin secretion in humans." European Journal of Endocrinology 153, no. 3 (2005): 397–402. http://dx.doi.org/10.1530/eje.1.01981.

Full text
Abstract:
Objective: It is well known that i.m. glucagon administration stimulates GH and cortisol release in humans, although the mechanisms are unclear. These effects are similar to those described for ghrelin on somatotroph and corticotroph function. The aim of the present study was to investigate the role of ghrelin in mediating the stimulatory effects of glucagon and to evaluate the effect of glucagon on ghrelin secretion. Design and methods: We studied the endocrine and metabolic response to i.m. glucagon administration in 24 subjects (14 men, 10 women; age 19–65 years; body mass index, 25.3 ± 1 k
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!